home

Culturally tailored type 2 diabetes programs may benefit Hispanic patients

Healthhealio2016-04-13 09:51 Read   72

Among Hispanic patients with type 2 diabetes, involvement of family members in a culturally targeted intervention program may yield improvements in glycemic control, diabetes knowledge, self-efficacy and physical health-related quality of life.

4D Pharma Acquires Instituto Biomar

EVENTSgenengnews2016-04-13 09:37 Read   84

Drug developer 4D Pharma said today it has acquired the production assets of Instituto Biomar, a contract research organization specializing in microbial fermentation, for up to €6 million ($6.8 million).

Elanco Gets FDA Nod on Biological Drug for Dairy Cows

R&Dxconomy2016-04-13 09:16 Read   89

A mastitis diagnosis in a cow spells trouble for a dairy farmer, who faces certain loss in milk production and possible loss of the cow. Antibiotics can treat this infection of the udder, but these drugs have fallen out of favor due to growing drug resistance.

Post-Shkreli KaloBios pledges transparent pricing

EVENTSpmlive2016-04-13 09:07 Read   86

 A company drawn into the price gouging scandal has promised to adhere to an affordable and transparent pricing policy for its drugs in future.

Health Tip: Dig into the Fresh Foods of Spring

Healthdrugs2016-04-13 08:52 Read   100

With the arrival of spring comes freshly grown foods.

Altarum: Health spending continues to slow in February

Healthhealthcarefinancenews2016-04-13 08:31 Read   73

Health spending has also held steady at 18 percent of gross domestic product for four consecutive months from October 2015 through January 2016.

Big year at Amgen delivers $2M pay hike for CEO Bradway, to $16M

R&Dfiercepharma2016-04-12 13:18 Read   88

Amgen ($AMGN) had a big year in 2015, as its newly filed proxy statement takes pains to emphasize. Revenue grew to $21.7 billion, an 8% hike.

Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates

EVENTSbusinesswire2016-04-12 13:05 Read   105

“The long-term collaboration with Celgene is an important component of our plan to develop our engineered T cell platform rapidly and effectively for the benefit of patients around the world, and we are encouraged by the progress we are making together.”

Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc

EVENTSstockhouse2016-04-12 12:58 Read   97

Tobira gains rights to second asset for NASH in North America, Europe & Australia First combination study with cenicriviroc to begin late 2016 Conference Call Scheduled for today at 8:30 a.m. ET

Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics

EVENTSregeneron2016-04-12 11:27 Read   86

Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of the CRISPR/Cas platform.

Please don’t hate us anymore; KaloBios’ new CEO takes a drug pricing oath

EVENTSfiercebiotech2016-04-12 11:15 Read   65

Biotech companies like KaloBios rarely like to publicly discuss their drug pricing strategies. It’s not a popular topic and they typically don’t have any products on the market that need to be priced anyway. But then, most biotech companies don’t have to distance themselves from one-time CEOs like Martin Shkreli.

Viamet Revisits IPO Plans, This Time With More Dataea

EVENTSxconomy2016-04-12 11:08 Read   73

Viamet Pharmaceuticals is taking another swing at the public markets, filing plans for an initial public offering intended to finance the work needed to bring its lead antifungal drug to the brink of late-stage clinical studies in two types of infections.